secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-11-27T23:59:59+00:00
Accession:  0001140361-23-054630
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant subsidiary Priovant's Phase 2 lupus study of oral brepocitinib fails primary endpoint
--------------------------------------------------------------------------------

- Oral brepocitinib did not meet primary endpoint of SRI-4 at Week 52 in moderate-to-severe active lupus.
- Highest placebo response rate observed in any significant SLE study prevented differentiation; active arm showed high SRI-4 rates.
- Priovant will not progress brepocitinib in SLE but continues in non-infectious uveitis and dermatomyositis.
- Topline results for NIU Phase 2 expected Q1 2024; dermatomyositis Phase 3 topline in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123054630/0001140361-23-054630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123054630/ef20015420_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-054630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer